Inhibitor Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a INTI research report →
Price Chart
About the company
Inhibitor Therapeutics, Inc. , established in 1992 and based in Tampa, Florida, is a pharmaceutical development enterprise. The company is dedicated to inventing and commercializing medical treatments for patients in the United States who suffer from various cancerous and non-cancerous cell proliferation conditions.
- CEO
- Francis E. O'Donnell Jr.
- IPO
- 2013
- Employees
- 8
- HQ
- Tampa, FL, US
Get TickerSpark's AI analysis on INTI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $15.36M
- P/E
- -4.66
- PEG
- -1.04
- P/S
- 0.00
- P/B
- -6.03
- EV/EBITDA
- -4.46
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 227.11%
- ROIC
- -689.90%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-3,426,653
- Net Income
- $-3,300,337+1.2%
- EPS
- $-0.02+1.5%
- OCF Growth
- +0.1%
- FCF Growth
- +0.1%
- 52W High
- $0.12
- 52W Low
- $0.04
- 50D MA
- $0.08
- 200D MA
- $0.07
- Beta
- -0.71
- RSI (14)
- 59
- Avg Volume
- 9.23K
No earnings-call transcripts are available for INTI yet.
- Free Float
- 44.9%
- Shares Outstanding
- 172.57M
- Float Shares
- 77.56M
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 1, 26 | Black Robe Capital LLC | other | 3,200,000 |
| May 4, 26 | OSMAN RONALD E | other | 50,000 |
| May 4, 26 | Yanez Michelle | other | 50,000 |
| May 4, 26 | SEARS SAMUEL P JR | other | 50,000 |
| May 4, 26 | ODONNELL FRANCIS E JR | other | 50,000 |
| May 4, 26 | Jerman Michael Allen | other | 50,000 |
| May 5, 26 | Vasisht Niraj | other | 50,000 |
| Apr 1, 25 | Vasisht Niraj | other | 50,000 |
| Apr 1, 25 | Yanez Michelle | other | 50,000 |
| Apr 1, 25 | SEARS SAMUEL P JR | other | 50,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our INTI coverage
Recent articles, reports, and earnings notes.
No research on INTI yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate INTI report →Inhibitor Therapeutics Provides Clinical, Formulation and IP Update on Itraconazole Program for Gorlin Syndrome
globenewswire.com · Mar 31
Complement Inhibitor Therapeutics Pipeline Developments Research Report 2024
globenewswire.com · Dec 5
Complement Inhibitors Clinical Trial Pipeline Analysis: 40+ Key Companies Shaping the Future of Complement Inhibitor Therapeutics | DelveInsight
globenewswire.com · Oct 28
Inhibitor Therapeutics, Inc. Provides Update on its Clinical Development Plan
globenewswire.com · Aug 22
3 Intriguing Stocks to Watch as Earnings Approach
zacks.com · May 22
Introducing Inhibitor Therapeutics, Inc. New Scientific Advisory Board
prnewswire.com · Dec 19
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.